The role of interleukin-1 beta in inflammation and the potential of immune-targeted therapies

Interleukin-1 beta (IL-1β) has emerged as an important therapeutic target, due to its key role in mediating inflammation and tissue damage in different disorders. This study presents a thorough review of the conditions in which (IL-1β) is playing an important role and a summary of the new and ongoing treatments aimed at suppressing its activity. Furthermore, we explored currently available IL-1β targeted treatments, such as IL-1 inhibitors like Canakinumab and Anakinra, and also explained their work at molecular level in reducing inflammation. IL-1β is targeted in inflammatory illnesses in treatment that are beneficial, but there are drawbacks as well which includes the requirement for customized treatment plans, drug resistance, and unpleasant effects. This study also underlines the recent advancements in IL-1β targeted therapies, shedding light on novel approaches.